Terns Reports Topline Results from Early-Stage NASH Study

Terns Pharmaceuticals Inc TERN reported topline results from Part 1 of Phase 1b AVIATION Trial of TERN-201 for treating patients with non-alcoholic steatohepatitis (NASH).  

  • Part 1 of the AVIATION Trial met the primary safety endpoint. Compared to placebo, 10 mg TERN-201 was generally well-tolerated with a similar incidence of adverse events (AEs) between the treatment group and placebo. 
  • All AEs were mild to moderate. 
  • While treatment with TERN-201 10 mg resulted in near-complete inhibition of plasma VAP-1 in most subjects, there were no meaningful changes in exploratory serum or imaging NASH biomarkers with TERN-201 10 mg relative to placebo.
  • Related: Terns' Potential NASH Candidate Shows Potent Liver Target Engagement.
  • Part 2 of the AVIATION Trial assessing 20 mg of TERN-201 is ongoing, with topline results expected in 2H of 2022. 
  • Terns will continue to analyze Part 1 of the AVIATION Trial results to evaluate the next steps for the TERN-201 program.
  • Terns looks forward to the planned initiation of Phase 2a trial of TERN-501 alone and in combination with TERN-101 for NASH in 1H of 2022 and Phase 1 trial of TERN-601 agonist for obesity in 2023.
  • Price Action: TERN shares closed 5.59% higher at $3.21 during after-hours trading on Monday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareMoversTrading IdeasGeneralBriefsNon Alcoholic steatohepatitisPhase 1 Trial
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!